Clinical Trial Update: Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density [Phase 3]

View source ↗

Summary

A Phase 3 multicenter trial assessing changes in bone mineral density after switching from protease inhibitors to dolutegravir in HIV-1-infected subjects with l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED